These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26202296)

  • 1. Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.
    Montesi L; Mazzotti A; Moscatiello S; Forlani G; Marchesini G
    Hepatol Int; 2013 Dec; 7 Suppl 2():814-22. PubMed ID: 26202296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, insulin resistance, NASH and hepatocellular carcinoma.
    Yu J; Shen J; Sun TT; Zhang X; Wong N
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):483-91. PubMed ID: 23876851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
    Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
    Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: The role of insulin resistance in nonalcoholic fatty liver disease.
    Utzschneider KM; Kahn SE
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4753-61. PubMed ID: 16968800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.
    Kitade H; Chen G; Ni Y; Ota T
    Nutrients; 2017 Apr; 9(4):. PubMed ID: 28420094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Steatosis and steatohepatitis in diabetic patient].
    Hůlek P; Dresslerová I
    Vnitr Lek; 2011 Apr; 57(4):364-7. PubMed ID: 21612059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of the metabolic syndrome in the USA.
    McCullough AJ
    J Dig Dis; 2011 Oct; 12(5):333-40. PubMed ID: 21091931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists.
    Scheen AJ; Luyckx FH
    Acta Clin Belg; 2003; 58(2):81-91. PubMed ID: 12836490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding.
    van Citters GW; Kabir M; Kim SP; Mittelman SD; Dea MK; Brubaker PL; Bergman RN
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5191-8. PubMed ID: 12414891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and hepatocarcinogenesis.
    Sasaki Y
    Clin J Gastroenterol; 2010 Dec; 3(6):271-8. PubMed ID: 26190483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
    Byrne CD
    Diabet Med; 2012 Sep; 29(9):1098-107. PubMed ID: 22672330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes.
    Lewis GF; Carpentier A; Adeli K; Giacca A
    Endocr Rev; 2002 Apr; 23(2):201-29. PubMed ID: 11943743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.